Reported Sunday, Longboard Pharmaceuticals Reports Interim Results From Phase 1b/2a PACIFIC Study, Showing 57.7% Seizure Reduction In DEE Patients
Portfolio Pulse from Benzinga Newsdesk
Longboard Pharmaceuticals reported interim results from its Phase 1b/2a PACIFIC study, showing a 57.7% reduction in seizures for DEE patients treated with Bexicaserin. The drug demonstrated favorable safety and tolerability. Full data is expected early next year.
September 09, 2024 | 7:51 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Longboard Pharmaceuticals' interim results from the PACIFIC study show a significant 57.7% reduction in seizures for DEE patients using Bexicaserin, with favorable safety and tolerability. This positive data could boost investor confidence.
The significant reduction in seizures and favorable safety profile of Bexicaserin in the interim results are likely to positively impact Longboard Pharmaceuticals' stock. Investors may view this as a promising development in the treatment of DEE, potentially increasing demand for LBPH shares.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100